IRIX IRIDEX Corporation
$0.75▲ +1.11%
Healthcare
Other
Volume 9.4K
Avg Volume (10D) 57.6K
Key Metrics & Fundamentals
Market Cap
$13.24M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.61 - 1.65
% vs 50 MA
3.73%
% vs 200 MA
-28.29%
RSI-14
49.2
MACD Histogram
-0.0100
Beta (1Y vs SPY)
0.88
Free Cash Flow
$124,000
Gross Rev
$12.57M
Gross Profit
$4.30M
EBITDA
-$667,000
COGS
$8.27M
Operating Exp
$5.33M
Operating Income
-$1.03M
EBIT
-$1.03M
Pretax Income
-$1.20M
Net Income
-$1.27M
EPS (Diluted)
-0.07
Price & Volume History
Loading chart…
Recent News
Iridex Announces the Publication of Two-Year Independent Study Supporting Benefits of MicroPulse® Technology for Early to Advanced Glaucoma
GlobeNewswire · Oct 12, 2026 7:00 AM ET
Iridex Completes Relocation of Manufacturing Facility to San Jose, California
GlobeNewswire · Oct 5, 2026 7:00 AM ET
IRIDEX (IRIX) Q2 2026 Earnings Call Transcript
Motley Fool · Aug 25, 2026 6:59 PM ET
IRIDEX Q2 Loss Widens Y/Y as Retina Weakness Weighs, Stock Down 15%
Zacks · Aug 25, 2026 1:43 PM ET
IRIDEX Corp (IRIX) (Q2 2026) Earnings Call Highlights: Cyclo-G6 Surges 35% as Company Achieves ...
GuruFocus.com · Aug 19, 2026 1:00 AM ET
IRIDEX Corporation Q2 2026 Earnings Call Summary
Moby · Aug 18, 2026 8:21 PM ET
Iridex: Q2 Earnings Snapshot
Associated Press · Aug 18, 2026 4:15 PM ET
Iridex Reports Second Quarter 2026 Financial Results
GlobeNewswire · Aug 18, 2026 4:05 PM ET
Iridex to Report Second Quarter 2026 Financial Results on August 18, 2026
GlobeNewswire · Aug 4, 2026 4:05 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See IRIX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.